Patient Stories

Transcript

Hello, my name is Dr. Grajales-Cruz. I'm a Board-Certified hematology oncologist with a focus on treating patients with multiple myeloma. I'm here today to provide information regarding treatment with ELREXFIO also known as elranatamab and what your experience may look like.

I'm joined by Louis; he'll shed some light on his experience as a patient with multiple myeloma and his treatment journey with ELREXFIO.

Let's talk about multiple myeloma for a moment.

As you may know, multiple myeloma is a type of blood cancer that arises from plasma cells inside the bone marrow.

In healthy bone marrow, plasma cells produce antibodies to help fight infection.

In multiple myeloma, plasma cells are transformed into cancer cells that grow out of control, crowding out the normal cells that help fight infection.

There has been a remarkable evolution of multiple myeloma treatments over the years. Since 2010 there have been more than a dozen therapies approved and in the past few years several treatments have emerged with more on the horizon.

This includes standard therapy options like immunotherapies.

The treatment we will talk about today is ELREXFIO also known as elranatamab.

ELREXFIO is a prescription medication used to treat adults with multiple myeloma who have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, and their cancer has come back or did not respond to prior treatment.

So, how does it work? ELREXFIO is a type of treatment called a BCMA-directed antibody, also known as a bispecific. It destroys myeloma cells by binding to both CD3, a protein found on the surface of T cells, and BCMA, a protein found on the surface of B cells. ELREXFIO binds to both myeloma cells and T cells then activating the T cells to help destroy myeloma cells.

ELREXFIO was studied in a clinical trial of people with relapsed or refractory multiple myeloma.

In a group of 97 patients who had never tried a BCMA-directed therapy and had already been on at least 4 prior treatment regimens, 58% achieved a response.

Most of the responses were a very good partial response or better.

Of people who responded to ELREXFIO, 82% were predicted to still be responding at 9 months, which is known as the duration of response rate.

ELREXFIO was approved based on patient responses and durability of responses. There are ongoing studies to confirm its clinical benefit.

Let's talk about how ELREXFIO is administered. It's given by your healthcare provider as an injection under your skin, what we call a subcutaneous injection, usually in your stomach area. Your thigh or another area of your body may also be used.

ELREXFIO is also a monotherapy, or a single therapy which means it's not given in combination with other multiple myeloma therapies.

Now, let's talk about what you can expect starting ELREXFIO.

During your first week you'll begin with 2 "Step-up" doses of ELREXFIO. Building up to a full dose, which will help your body's immune system adjust. You'll be hospitalized during these first 2 doses so your healthcare team can monitor your symptoms for cytokine release syndrome (CRS) or neurological problems.

Your first full treatment dose will be your 3rd dose, which you will receive on Day 8.

Before each step-up dose and the first full treatment dose of ELREXFIO, you will receive medicines to help reduce your risk of CRS, a serious side effect.

Then after completing the "Step-up dosing" schedule you will likely begin weekly treatment with ELREXFIO at your healthcare provider office or another outpatient setting.

After 6 months of treatment, if you have had a partial response or better for at least 2 months, an every other week dosing schedule could be right for you. After maintaining a response on an every other week dosing schedule for 6 months, a once monthly dosing schedule, every 4 weeks, could be right for you.

ELREXFIO may cause side effects that are serious, life-threatening, or can lead to death, including cytokine release syndrome and neurologic problems.

CRS is common during treatment with ELREXFIO.

Always tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS or neurologic problems.

ELREXFIO is available only through a restricted program called the ELREXFIO Risk Evaluation and Mitigation Strategy, or REMS. It is your care team's responsibility to complete the REMS program prior to your treatment, but important that you carry your Patient Wallet Card with you.

Hi, my name is Louis. I've been living with multiple myeloma for eight years and I have been on several treatments over the years. After each treatment eventually stopped working it got harder and harder to find a medicine that was going to work.

After my most recent relapse, my doctor recommended that I try ELREXFIO. We discussed the potential side effects and together we decided to move forward with the treatment.

Overall, the hospital experience went extremely well. It was like clockwork, and their people were very well-trained. When I was supposed to receive treatment on the hour, the person administering my treatment came in on the hour. No delay. No nothing. It was really quite impressive.

It was comforting to have them monitoring for side effects so often.

A week after my "Step-Up" dosing in the hospital I went to my doctor's office and got the beginning of what they call the first dose.

I began receiving once-a-week treatments. Then it went to every two weeks and now I go once a month.

My current treatment schedule is great. We travel. We love to go cruising. We can spend more time visiting our grandkids.

This is just my experience; others may be different.

If you'd like to learn more or are getting ready to talk with your doctor, head over to ELREXFIO.com.